Women in Southeast Brazil experienced much shorter TTT in days when presenting with triple-negative (mean: 74.7 days; P = .003), HER2-positive (mean: 76.1 days; P = .005), or stage III breast cancer (mean: 78.9 days; P = .03) compared to stage I or stage II luminal breast cancer (93.0 days) (Table 4). This evidence concerns the gene ERBB2 and breast carcinoma.